As part of the U.S. Food and Drug Administration’s efforts to promote drug competition and patient access, there are advanced many policies aimed at making it more efficient to bring generic competition to the market. These are drugs that, by nature of their formulation or delivery systems for example, are harder to “genericize” under our traditional approaches. As a result, these drugs often face less competition.